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Abstract
Prospective, population-based studies that recruit participants in mid-life are valuable resources for dementia research. 
Follow-up in these studies is often through linkage to routinely-collected healthcare datasets. We investigated the accuracy 
of these datasets for dementia case ascertainment in a validation study using data from UK Biobank—an open access, 
population-based study of > 500,000 adults aged 40–69 years at recruitment in 2006–2010. From 17,198 UK Biobank 
participants recruited in Edinburgh, we identified those with ≥ 1 dementia code in their linked primary care, hospital admis-
sions or mortality data and compared their coded diagnoses to clinical expert adjudication of their full-text medical record. 
We calculated the positive predictive value (PPV, the proportion of cases identified that were true positives) for all-cause 
dementia, Alzheimer’s disease and vascular dementia for each dataset alone and in combination, and explored algorithmic 
code combinations to improve PPV. Among 120 participants, PPVs for all-cause dementia were 86.8%, 87.3% and 80.0% 
for primary care, hospital admissions and mortality data respectively and 82.5% across all datasets. We identified three algo-
rithms that balanced a high PPV with reasonable case ascertainment. For Alzheimer’s disease, PPVs were 74.1% for primary 
care, 68.2% for hospital admissions, 50.0% for mortality data and 71.4% in combination. PPV for vascular dementia was 
43.8% across all sources. UK routinely-collected healthcare data can be used to identify all-cause dementia in prospective 
studies. PPVs for Alzheimer’s disease and vascular dementia are lower. Further research is required to explore the geographic 
generalisability of these findings.
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Introduction
Dementia is a growing public health concern worldwide 
[1], and prospective, population-based studies are necessary 
to improve our understanding of its natural history and risk 
factors.
UK Biobank (UKB, www.ukbio bank.ac.uk) is a very large, 
prospective, population-based cohort study that was estab-
lished to facilitate research into the determinants of health and 
disease, primarily in middle and old age [2]. UKB collected a 
wealth of exposure sociodemographic, lifestyle, environmental 
and health information during the baseline assessment, along 
with a range of physical measures and cognitive testing. Fur-
ther enhancements include genotyping, repeat cognitive test-
ing, dietary questionnaires and multimodal imaging. UKB is 
an open access resource, and any bona fide researcher around 
the world can apply to use its data for health-related research 
in the public interest. To date, UKB has approved projects to 
study dementia and cognitive disorders across a wide range 
of topics, including: identifying genetic, environmental and 
lifestyle risk factors for dementia; establishing the relationship 
between neuroimaging findings and cognition and developing 
dementia risk prediction models (www.ukbio bank.ac.uk/appro 
ved-resea rch).
Follow-up for disease outcomes in UKB is largely via link-
ages to routinely-collected, coded clinical healthcare datasets 
[3]. UKB receives regularly updated linkages to national 
hospital admissions, cancer and mortality data for all partici-
pants, and has obtained linked primary care data for > 200,000 
participants.
Attrition during follow-up can be a source of bias in longi-
tudinal studies, and participants with poorer cognitive ability 
are at a greater risk of loss to active follow-up [4]. Passive 
follow-up using comprehensive data linkage minimises attri-
tion and provides a cost-effective means of identifying disease 
cases in prospective studies.
These datasets must, however, identify cases with a high 
positive predictive value (PPV) (i.e., a high proportion of those 
with dementia codes in these datasets must be true dementia 
cases). Previous validation studies in the UK have investigated 
the PPV of single datasets, rather than in combination [5–8].
We aimed to estimate the PPV of dementia coding in UK 
primary care, hospital admissions and national mortality data-
sets alone and in combination using data from UKB.
Methods
Study design
We identified UK Biobank participants recruited in Edin-
burgh, Scotland, who had ≥ 1 dementia code in their linked 
UK hospital admissions, mortality or primary care data. We 
compared the coded diagnoses to diagnoses based on full-
text electronic medical record (EMR) review by clinicians 
with dementia expertise as a reference standard.
Recruitment to UK Biobank
Details regarding participant recruitment to UKB are pub-
lished elsewhere [9, 10]. Briefly, between 2006 and 2010, 
UKB recruited 500,000 participants aged 40–69 years who 
were registered with the UK National Health Service (NHS) 
and living near one of 22 recruitment centres.
Datasets and dementia codes
In the UK, mortality and hospital data are currently coded 
using the International Classification of Diseases version 10 
(ICD-10) while primary care data are coded using the Read 
coding system (version 2 or 3). ICD-10 contains almost 
exclusively diagnostic codes, whereas the Read coding sys-
tem includes diagnostic and administrative (e.g. specialist 
referral) codes (along with codes for prescriptions, proce-
dures, symptoms and signs). We used a comprehensive four-
stage process to compile a list of dementia ICD-10 and Read 
V2 codes (Online Resource 1), aimed at identifying cases 
with a high PPV, rather than at maximising sensitivity.
Study population
We excluded participants with no correspondence in the 
local (National Health Service [NHS] Lothian) EMR sys-
tem, as they are likely to obtain their healthcare in a differ-
ent NHS area. We included all identified participants with 
any correspondence in the EMR (even if not pertaining to 
dementia) to avoid over-estimation of PPV due to informa-
tion bias. The start date was the earliest code in any dataset 
and the end date was the latest date at which all three data-
sets were available (September 2015).
Reference standard
The EMR contains hospital inpatient and outpatient cor-
respondence as well as investigation results. To create case 
vignettes for adjudication, we extracted letters that referred 
to cognition or a diagnosis of dementia, along with any rel-
evant neuroimaging and laboratory reports. We removed 
all personally identifying information from the vignettes. 
Using the case vignettes and a pre-piloted adjudication form 
(Online Resource 2), a clinician with dementia expertise 
(JO’B, SP, TR, DB or TW) determined whether dementia 
was present (‘all-cause dementia’) and, if so, whether a sub-
type diagnosis could be made. Diagnostic criteria were pro-
vided (Online Resource 3) [11–17]; however, since patients 
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are frequently diagnosed with dementia in routine clinical 
practice without meeting rigorous formal criteria, the adju-
dicators could select a ‘formal criteria not met but diagno-
sis likely’ option, to indicate a diagnosis that they would 
make in their practice. We blinded researchers extracting the 
vignettes and adjudicators to the participants’ codes.
Inter‑rater agreement
Two clinicians independently adjudicated a random sub-
sample of 25% of cases so that we could measure inter-rater 
agreement. We calculated the percentage agreement and 
Cohen’s kappa statistic for whether dementia was present 
or not and, where both adjudicators agreed dementia was 
present, the subtype diagnosis.
Statistical analyses
For all-cause dementia, Alzheimer’s disease and vascular 
dementia, we calculated the PPV for each dataset separately, 
and for all three combined.
For all-cause dementia, true positive cases were those 
where the adjudicator recorded dementia as being present, 
with or without meeting diagnostic criteria. False posi-
tive cases were those where the adjudicator indicated that 
dementia was not present or where there was insufficient 
information to make a diagnosis of dementia. Adjudicating 
diagnoses for participants with insufficient information in 
their medical record to confirm or refute dementia may lead 
to an underestimate of PPV, so we also performed a sensitiv-
ity analyses in which we removed these participants from the 
PPV calculation for each dataset.
For dementia subtypes, cases were true positives if the 
adjudicator indicated that a particular subtype diagnosis 
could be made, with or without meeting the particular diag-
nostic criteria. False positive cases were those where it was 
not possible to determine the subtype diagnosis or if the 
adjudicator selected an alternative subtype diagnosis. We 
combined diagnoses of dementia with Lewy Bodies (DLB), 
Parkinson’s disease dementia (PDD) and frontotemporal 
dementia (FTD) into an ‘other specific dementias’ category 
due to small numbers for these diagnoses separately.
We calculated PPV as the number of true positives 
divided by the number of true and false positives combined, 
and calculated confidence intervals using the Clopper–Pear-
son (exact) method.
We investigated the effects on PPV and the numbers of 
cases ascertained by implementing additional criteria: using 
diagnostic versus administrative codes in primary care data; 
using subtype codes (such as Alzheimer’s disease or vascu-
lar dementia) to identify dementia of any cause; and requir-
ing ≥ 2, ≥ 5 and ≥ 10 codes to identify all-cause dementia or 
Alzheimer’s disease. Based on these results, we identified 
algorithms that appeared to optimise a high PPV and good 
case ascertainment (implying reasonable sensitivity), as 
these are most likely to be of value to researchers using UKB 
data for dementia research.
We compared demographic data for false positives and 
true positives for all-cause dementia (age at recruitment, 
sex, age at first code, number of codes, whether participants 
died during follow-up and socioeconomic status as measured 
by the Townsend Deprivation Index [TDI]). The TDI was 
divided into quintiles, ranging from 1 (lowest deprivation) 
to 5 (highest deprivation), based on 2001 census data [18]. 
We used Microsoft SQL 2012 for data management and con-
ducted statistical analyses in R (www.r-proje ct.org).
Results
Participant characteristics
Of the 17,198 UKB participants recruited in Edinburgh, 126 
had ≥ 1 dementia code in any dataset. Of these, there were no 
free-text entries in the medical record system for six partici-
pants, leaving 120 participants in the study (Fig. 1).
Of the 120 included participants, 64 (53.3%) were female, 
median age of recruitment was 67 years (range 43–70 years) 
and median age at receiving first dementia code was 70 years 
(range 41–77 years). Twenty-five participants (20.8%) died 
during follow-up.
Across the 120 participants, there were 633 demen-
tia codes in total, with a median of four codes per person 
(range 1–35). Of 389 primary care codes, 168 (43.2%) were 
diagnostic and 221 (56.8%) were administrative. The first 
dementia code was in primary care data in 79.2% of par-
ticipants, hospital admissions data in 18.3% and mortality 
data in 2.5%. Of the 120 identified cases, 62 (51.7%) were 
found only in primary care data. The distribution of identi-
fied cases across the three datasets is displayed in Fig. 2.
Fig. 1  Flow diagram of participant selection
 T. Wilkinson et al.
1 3
Reference standard diagnoses
Adjudicators determined that dementia of any cause was 
present in 99/120 participants. Of these, 77 (77.8%) met 
the formal ICD-10 diagnostic criteria for dementia. Adju-
dicators were able to make a subtype diagnosis in 79/99 
(79.8%) of cases (Fig. 3), with 38/79 (48.1%) meeting for-
mal subtype diagnostic criteria. Alternative diagnoses for 
the cases judged not to have dementia were: mild cognitive 
impairment (9), affective disorders (2), delirium (1), stroke 
(1), unclear due to diagnostic uncertainty (2). Adjudicators 
deemed six further participants as not having dementia due 
to lack of relevant correspondence. In these cases, there was 
no correspondence in the medical record that mentioned 
cognitive symptoms, a diagnosis of dementia, or a relevant 
alternative diagnosis.
Inter‑rater agreement
Two adjudicators independently reviewed 30/120 (25%) of 
cases. The percentage agreement and kappa coefficients for 
all-cause dementia and dementia subtypes are displayed in 
Table 1.
PPV for all‑cause dementia, Alzheimer’s disease 
and vascular dementia
For all-cause dementia, PPVs were 86.8% (95% CI 
78.8–92.6), 87.3% (75.5–94.7) and 80.0% (44.4–97.5) in 
primary care, hospital admissions and mortality data respec-
tively. PPVs were 84.5% (72.6–92.7) for hospital admissions 
and mortality data in combination, and 82.5% (74.5–88.8) 
across all datasets (Fig. 4). For subtype codes to identify 
those specific subtypes (e.g., Alzheimer’s disease codes 
identifying participants with Alzheimer’s disease), PPVs for 
all datasets combined were 71.4% (58.7–82.1) for Alzhei-
mer’s disease and 43.8% (19.8–70.1) for vascular dementia.
Sensitivity analysis: PPVs for all‑cause dementia
When we removed from the analysis the six participants 
who had insufficient information in their medical record to 
confirm or refute a dementia diagnosis, PPVs for all-cause 
dementia increased to 88.5% (80.7–93.9) in primary care 
data, 92.3% (81.5–97.9) in hospital admissions, 88.9% 
(51.8–99.7) in mortality data, and 86.8% (79.2–92.4) across 
all datasets.
Fig. 2  Area proportional Euler diagram indicating the datasets from 
which dementia cases were identified (n = 120). Distribution of cases 
identified at any time until end of follow-up (September 2015)
Fig. 3  Adjudicator subtype diagnoses of the 99 cases adjudicated 
to have dementia. AD Alzheimer’s disease, VaD vascular dementia, 
Mixed mixed AD/VaD, DLB/PDD dementia with Lewy bodies and 
Parkinson’s disease dementia, FTD frontotemporal dementia
Table 1  Adjudicator agreement
Percentage agreement and kappa coefficients for whether adjudicators agreed on the presence or absence of 
dementia or the particular subtype
a Among 20 cases where both adjudicators thought that all-cause dementia was present
Agreement Number agreed/total 
number
Percentage agreement 
(%)
Kappa coefficient (95% CI)
All-cause dementia 27/30 90 0.76 (0.48–1.00)
Dementia  subtypesa 13/20 65 0.57 (0.29–0.84)
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Effects of additional criteria on PPV and case 
ascertainment for all‑cause dementia
Figure 5 shows the effects of additional criteria on PPV 
and the number of cases identified. For primary care data, 
using only diagnostic codes (without administrative codes) 
appeared to increase PPV from 86.8% (diagnostic and 
administrative codes combined) to 90.1% without a large 
loss of cases (106 vs. 101, and only one of the lost cases was 
a true positive), although confidence intervals overlapped.
Using dementia subtype codes only to identify all-cause 
dementia resulted in an increase in PPV from 82.5 to 91.7%; 
however, only 84 cases were identified, compared to 120 
using the broader code list (22/36 lost cases were true posi-
tive cases). The PPVs for Alzheimer’s disease, vascular 
dementia and the other specified subtype dementia codes to 
identify all-cause dementia were 93.7%, 87.5% and 83.3% 
respectively.
For all-cause dementia, PPV increased from 58.3% in 
participants with only one dementia code, to 88.5% for those 
Fig. 4  Positive predictive values for datasets, alone and in combina-
tion, stratified by dementia subtype. FTD frontotemporal dementia, 
PDD Parkinson’s disease dementia, DLB dementia with Lewy bodies. 
PPVs displayed for datasets where n ≥ 5. FTD, PDD and DLB com-
bined into ‘other dementias’ category due to small numbers for each 
disease alone
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with two or more codes, but with a reduction in the number 
of cases ascertained (120 vs. 96, true positive case numbers 
99 vs. 85).
Table 2 summarises the PPVs and numbers of cases 
ascertained for three algorithms that appeared to balance a 
high PPV with good case ascertainment.
Demographics of true and false positives
Demographic information for participants judged to be true 
positives and false positives are displayed in Table 3. False 
positive cases were less often female, had fewer codes, and 
were of lower average socioeconomic status.
Discussion
We have estimated the accuracy of using UK routinely-
collected healthcare datasets, alone and in combination, 
to identify dementia cases, demonstrating PPV estimates 
of 80–87%. For subtype diagnoses, the PPV for identify-
ing Alzheimer’s disease cases was lower than for all-cause 
Fig. 5  Effect of additional criteria on positive predictive values and 
numbers of cases ascertained. FTD Frontotemporal dementia, PDD 
Parkinson’s disease dementia, DLB dementia with Lewy bodies. ≥ 10 
and ≥ 20 Alzheimer’s disease codes not shown due to small numbers 
(< 5). *Any Alzheimer’s disease, vascular dementia, FTD, PDD or 
DLB code to identify dementia of any cause
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dementia, but higher than that for vascular dementia (71% 
and 44% respectively across all datasets).
These PPV estimates are likely to be conservative, as we 
deemed potential dementia cases ‘false positives’ if there 
was insufficient information in the hospital medical record to 
confirm or refute a diagnosis of dementia. It is possible that 
some of these participants did have dementia, but relevant 
correspondence was missing. A sensitivity analysis, in which 
we excluded these participants from the PPV calculations, 
resulted in increased PPVs of 89–92% across the datasets. It 
is likely that the ‘true’ PPV lies between these conservative 
and less stringent estimates.
Acceptable levels of accuracy, and the relative impor-
tance of different accuracy metrics, depends on the context 
[19]. UKB is primarily used for research into the genetic and 
non-genetic determinants of disease [2]. In such analyses, 
where a sub-group within the cohort are identified based 
on their disease status, it is important to ensure that a high 
proportion of participants within the group truly do have 
the disease (high PPV) to minimise bias in effect estimates. 
A high specificity (the proportion of participants without 
the disease that do not receive a dementia code) is crucial 
in obtaining a high PPV, but is not in itself sufficient. In 
population-based prospective cohorts where dementia 
prevalence is low, the proportion of participants misclassi-
fied as having dementia (false positives) may be small (high 
specificity), even if the absolute numbers of false positives 
is high compared to the number of true positives (low PPV) 
[19]. Providing appropriate codes are used, the specificity of 
routinely collected healthcare data to identify disease cases 
in population-based studies is usually very high (98–100%) 
[20, 21]. For this reason, we designed our study to estimate 
the PPV of using routinely-collected healthcare data to iden-
tify dementia outcomes in UKB.
Primary care data is potentially a valuable resource for 
dementia case ascertainment. Our results show similar accu-
racy to hospital admissions and mortality data, in keeping 
with previous studies in this area [6, 7, 22]. Furthermore, 
52% of cases were found only in primary care data, suggest-
ing that using only hospital admissions and mortality data 
will miss cases. However, this finding is likely to be depend-
ent on the age of the cohort, because as the cohort ages, 
more participants are likely to appear in hospital admissions 
and mortality data.
We explored the effect of various code selection criteria 
on PPV and the numbers of cases ascertained. The addition 
of primary care administrative codes added few extra true 
positive cases and reduced PPV. In keeping with previous 
findings [5], using specific dementia subtype codes to iden-
tify all-cause dementia and requiring ≥ 2 codes across any 
dataset led to higher PPVs but fewer cases identified. We 
identified three algorithms that, in this study, balanced a 
high PPV with reasonable case ascertainment. These algo-
rithms include the use of primary care data, and to date, 
UKB has acquired linkage to primary care data for > 200,000 
of its participants. These algorithms can, therefore, only 
be employed on the subset of the cohort in whom primary 
care data are available. An alternative approach would be 
to rely only on identifying cases within hospital admissions 
and mortality data for the whole cohort (> 500,000). In our 
Table 2  Positive predictive value and case ascertainment in suggested algorithms to identify all-cause dementia cases in UK Biobank
P Primary care, H hospital admissions, M mortality, PPV positive predictive value, CI confidence intervals. TP true positive
*Administrative read codes excluded
Algorithm Number of codes required Dataset PPV (95% CI) Total (TP) 
cases identi-
fied
Any dementia code in any dataset ≥ 1 code in any dataset P, H & M 82.5% (74.5–88.8) 120 (99)
Two or more dementia codes in any dataset ≥ 2 codes in any dataset P, H & M 88.5% (80.4–94.1) 96 (85)
Any diagnostic code in primary care data* ≥ 1 diagnostic code P 90.1% (92.5–95.1) 101 (92)
Table 3  Demographics of participants who were adjudicated to be false positives, true positives and whole validation group
TDI Townsend deprivation index—divided into quintiles (1—lowest deprivation, 5—highest deprivation) based on 2001 census data [18]
Group Number of 
participants
Median age at 
recruitment (range)
Female (%) Median age at first 
code (range)
Median number of 
codes (range)
Died during 
follow-up (%)
Median 
TDI 
(range)
All 120 67 years (43–70) 64 (53.3) 70 years (41–77) 5 (1–35) 25 (20.8) 1 (1–5)
True positives 99 67 years (51–70) 54 (54.5) 71 years (52–77) 6 (1–35) 20 (20.2) 1 (1–5)
False positives 21 67 years (43–70) 10 (47.6) 68 years (41–76) 2 (1–8) 5 (23.8) 3 (1–5)
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study, this algorithm resulted in a PPV of 85%, but a reduc-
tion in case ascertainment from 120 to 58. Users of UKB 
data will need to select the approach that best suits their 
research question.
Sensitivity is another important accuracy metric to con-
sider when comparing methods of identifying disease out-
comes during follow-up in longitudinal studies. There is a 
trade-off between PPV and sensitivity, and any approach to 
identifying dementia cases must balance these in a way that 
is appropriate for the setting. Missing cases, and therefore 
a lower sensitivity, will reduce statistical power, but may 
also introduce bias if patients who are missed systemati-
cally differ from identified cases. We were unable to calcu-
late the sensitivity of routinely-collected healthcare data to 
identify dementia outcomes in our study, because to do so 
the ‘true’ number of people with dementia in a population 
must be known, including those who have dementia but are 
currently undiagnosed, and therefore not known to health-
care services. UK mortality data has been shown to identify 
45% of dementia cases, when diagnoses are taken from any 
position on the death certificate [21]. Sommerlad et al. [23] 
reported a sensitivity of 78% for hospital admissions data 
to identify dementia cases, using data from a large men-
tal healthcare database as a gold standard. However, these 
patients were already known to mental health services with 
a diagnosis of dementia, so this does not account for people 
who were undiagnosed, meaning the true sensitivity is likely 
to be lower. The ongoing Cognitive Function and Ageing 
II Dementia Diagnosis Study is likely to provide the best 
estimate of the sensitivity of UK primary care data for iden-
tifying dementia diagnoses [24].
Our study has several strengths: creating a comprehensive 
code list; blinding of adjudicators to the coded information; 
using expert clinical adjudicators as the reference standard; 
allowing clinicians to make diagnoses mirroring current 
diagnostic practice, rather than relying on strict diagnostic 
criteria; and measuring intra-adjudicator agreement, show-
ing it to be good for all-cause dementia.
There were some limitations, however. The UKB cohort 
is still relatively young, as indicated by the median age at 
first dementia code being 70 years, meaning our results 
may not be generalisable to settings with older popula-
tions. This is reinforced by the reference standard diagno-
ses, with a lower proportion of vascular dementia, mixed 
dementia and DLB cases than we would expect to see 
in older populations. Participants were all from a single 
centre in Scotland, and further research is necessary to 
ensure that our results are generalisable to other areas of 
the UK. Our sample size precluded in-depth analyses of 
vascular dementia and of other dementia subtypes such as 
DLB, PDD and FTD. The lack of a precise ICD-10 code 
for DLB means that we could only ascertain cases from 
primary care data. These are under-represented areas of 
epidemiological research using routinely-collected data, 
and a multi-centre study with longer follow up times will 
be necessary to accrue sufficient numbers. Lastly, our cho-
sen reference standard is a potential limitation. We used 
correspondence and investigation results within the hos-
pital EMR to adjudicate whether dementia was present. In 
some cases, the EMR may have been incomplete and there 
may have been additional information that would have 
been available to the clinician seeing the patient at the 
time of diagnosis. Our reference standard may therefore 
underestimate PPV by misclassifying some true demen-
tia cases as false positives. Whereas inter-rater agreement 
was good for all-cause dementia, it was only moderate for 
subtype diagnoses. This is unsurprising, given that demen-
tia subtype diagnoses lack objective diagnostic tests, and 
rely heavily on clinical judgement. It is well-recognised 
that many subtype diagnoses made in clinical practice do 
not agree with neuropathological data [25, 26], and so it 
is likely that our reference standard misclassified some 
diagnoses.
In conclusion, we have estimated the PPV of using UK 
routinely-collected healthcare datasets to identify cases 
of all-cause dementia, Alzheimer’s disease and vascular 
dementia during follow-up in large, prospective studies in 
the UK (specifically the UK Biobank resource) and have 
identified several algorithms that balance a high PPV with 
reasonable case ascertainment. Further research is required 
to investigate the potential biases inherent in using these 
data, the accuracy of coding in other dementia subtypes, 
and the generalisability of our findings to older ages and 
other geographical areas.
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